An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requirements and endoscopy frequency in patients with Rendu-Osler-Weber and gastrointestinal bleeding
- Conditions
- Rendu-Osler-Weber and Hereditary hemorrhagic telangiectasia10017959
- Registration Number
- NL-OMON43279
- Lead Sponsor
- Maag-, darm- en leverziekten
- Brief Summary
Trial is onging in other countries
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 11
- Patients with Rendu-Osler-Weber;- Symptomatic gastrointestinal bleeds out of telangiectasias;- Transfusion and / or endoscopy dependent: ;Transfusion: at least 2 blood and/or iron infusions in the 6 months before inclusion.;Endoscopy: at least one endoscopy with APC after the initial endoscopic treatment after diagnosis in the half year before inclusion or unsuitable for endoscopy.
- liver cirrhosis Child-Pugh C or acute liver failure
- Symptomatic cholecystolithiasis (without cholecystectomie)
- previous unsuccessful treatment with somatostatin analogues for the same indication (refractory anaemia due to telangiectasias) or current effective treatment with a somatostatin analogue
- current successful treatment with thalidomide
- severe diseases with life expectancy < 1 year
- patients with left ventricular assist devices (LVAD*s)
- pregnancy or nursing women or women who have a pregnancy wish in the studyperiod or who use anticonception inadequate
- current chemotherapy
- patients with a known hypersensitivity to SST analogues or any component of the pasireotide LAR formulations
- systemic cancer currently undergoing chemotherapy or radiation therapy
- no understanding of Dutch or English
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method